What question did this study set out to answer?

To explore the significance of KRAS gene amplification as an oncogenic driver and potential therapeutic target in human cancers.

Abstract PR005: KRAS amplification as de novo oncogenic alteration and therapeutic target in human cancers

View Full Paper

Ask AI

Bookmark

To explore the significance of KRAS gene amplification as an oncogenic driver and potential therapeutic target in human cancers.
Integrated genomic, structural, clinical, and functional analysis across three independent datasets.
Analyzed a total of 685,507 tumors for KRAS amplification prevalence.
Used whole-genome sequencing and FISH to investigate amplicon architectures.
Assessed the effects of wild-type KRAS overexpression in Rasless cells.
KRAS amplification occurred in approximately 2-3% of various cancers.
High-level KRAS amplification correlated with increased KRAS mRNA and protein expression.
KRAS amplification was linked to poorer overall survival, independent of KRAS mutation status.
Forced expression of KRAS in Rasless cells restored MAPK signaling and sensitivity to pan-RAS inhibitors.

No takes yet. Share an insight, caveat, or question.

Clinico-genomic analysis demonstrates KRAS amplification as an oncogenic driver in various cancers, indicating a new therapeutic target.

Awad et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark